Pacific Ridge Capital Partners LLC Invests $542,000 in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Key Points

• Pacific Ridge Capital Partners LLC acquired a new stake in Sensus Healthcare, purchasing 114,500 shares for approximately $542,000, representing about 0.69% of the company.
• Multiple hedge funds including JPMorgan Chase & Co. and Barclays PLC have also made new stakes in Sensus Healthcare, indicating increased institutional interest with 25.30% of the stock held by institutional investors.
• Sensus Healthcare's latest earnings report revealed a loss of ($0.16) EPS, missing estimates, while the company reported revenues of $8.34 million, exceeding consensus expectations of $7.23 million.

Pacific Ridge Capital Partners LLC bought a new position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 114,500 shares of the company's stock, valued at approximately $542,000. Pacific Ridge Capital Partners LLC owned about 0.69% of Sensus Healthcare as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in shares of Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after purchasing an additional 21,600 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Sensus Healthcare by 30.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock valued at $2,620,000 after buying an additional 88,953 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Sensus Healthcare by 81.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock valued at $1,039,000 after buying an additional 67,269 shares during the period. Bank of New York Mellon Corp lifted its holdings in Sensus Healthcare by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock valued at $672,000 after buying an additional 5,289 shares during the period. Finally, Marshall Wace LLP lifted its holdings in Sensus Healthcare by 99.6% in the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock valued at $915,000 after buying an additional 65,994 shares during the period. Institutional investors own 25.30% of the company's stock.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS traded up $0.02 during trading on Wednesday, hitting $5.27. 50,367 shares of the company traded hands, compared to its average volume of 182,095. The business's fifty day moving average is $4.84 and its 200 day moving average is $5.04. Sensus Healthcare, Inc. has a fifty-two week low of $4.01 and a fifty-two week high of $9.33. The firm has a market capitalization of $86.64 million, a price-to-earnings ratio of 52.61 and a beta of 1.34.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a net margin of 4.56% and a return on equity of 3.34%. The company had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million. On average, analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Maxim Group dropped their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Wall Street Zen lowered shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.